MRNA — Moderna Cashflow Statement
0.000.00%
Last trade - 00:00- $20.38bn
- $15.21bn
- $1.94bn
Annual cashflow statement for Moderna, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 12,202 | 8,362 | -4,714 | -3,561 | -2,822 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 196 | 285 | 286 | 446 | 501 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 1,308 | -3,455 | -139 | -78 | 233 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | 13,620 | 4,981 | -3,118 | -3,004 | -1,873 |
| Capital Expenditures | -284 | -400 | -707 | -1,051 | -202 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -8,239 | -4,776 | 4,913 | 3,000 | 2,148 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -8,523 | -5,176 | 4,206 | 1,949 | 1,946 |
| Financing Cash Flow Items | — | — | — | — | -24 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -873 | -3,448 | -1,377 | 56 | 593 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 4,224 | -3,643 | -289 | -999 | 668 |